Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis

Journal of Infectious Diseases

Volumn 173, Issue 1, 1996, Pages 18-23

  Kuppermann, Baruch D ^b   Assil, Kerry K ^c   Vuong, Chou ^e   Besen, Gilberto ^e   Wiley, Clayton A ^d   De Clercq, Erik ^e   Bergeron Lynn, Germaine ^e   Connor, James D ^e   Pursley, Michael ^e   Munguia, David ^e   Freeman, William R ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Sinskey Eye Institute   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR; LIPOSOME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG FORMULATION; DRUG POTENCY; DRUG TISSUE LEVEL; HERPES SIMPLEX VIRUS 1; INTRAVITREAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINITIS;

EID: 19144367116     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.1.18     Document Type: Article

References (11)

1. Pertel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J AIDS 1992;5:1069-74.
2. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE, Zidovudine Epidemiology Study Group. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992;166:1223-7.
3. + counts with the prevalence of cytomegalovirus retinitis and human immune deficiency virus-related non-infectious retinal vasculopathy in patients with the acquired immune deficiency syndrome. Am J Ophthalmol 1993;115:575-82.
4. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med 1993;329:1922-6.
5. Palestine AG, Stevens G Jr, Lane HC, et al. Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine. Am J Ophthalmol 1986;101:95-101.
6. Fanning MM, Read SE, Benson M, et al. Foscamet therapy of cytomegalovirus retinitis in AIDS. J AIDS 1990;3:472-9.
7. Biron KK, Fyfe JA, Stanat SC, et al. A human cytomegalovirus mutant resistant to the nucleoside analog 9-[2-hydroxy-1-(hydroxymethyl)ethoxy] guanine (BAW 759U) induces reduced levels of BW B759 U triphosphate. Proc Natl Acad Sci USA 1986;83:8769-73.
8. Erice A, Chou S, Biron KK, Stanant SC, Balfour HH Jr, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989;320:289-93.
9. Tatarowicz WA, Lurain NS, Thompson KD. In situ ELISA for the evaluation of antiviral compounds effective against human cytomegalovirus. J Virol Methods 1991;35:207-15.
10. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infections. J Infect Dis 1991;329:1922-6.
11. Flores-Aguilar M, Kuppermann BD, Quiceno JI, et al. Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis. Ophthalmology 1993;100:1022-31.